[{"AccountsPayableTradeCurrent_0_Q2_USD":166750.0,"OperatingLeaseWeightedAverageDiscountRatePercent_0_Q2_pure":0.0401,"OperatingLeasesFutureMinimumPaymentsDueThereafter_0_Q2_USD":313836.0,"OperatingLeasesFutureMinimumPaymentsDueInTwoYears_0_Q2_USD":298305.0,"OperatingLeasesFutureMinimumPaymentsDueInThreeYears_0_Q2_USD":246004.0,"OperatingLeasesFutureMinimumPaymentsDueInFourYears_0_Q2_USD":253384.0,"OperatingLeasesFutureMinimumPaymentsDueInFiveYears_0_Q2_USD":260985.0,"OperatingLeasesFutureMinimumPaymentsDueCurrent_0_Q2_USD":175419.0,"OperatingLeasesFutureMinimumPaymentsDue_0_Q2_USD":1388163.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":1297964.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":1084675.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":303488.0,"OperatingLeaseExpense_2_Q2_USD":168196.0,"OperatingLeaseExpense_1_Q2_USD":84113.0,"OperatingIncomeLoss_2_Q2_USD":-13835464.0,"OperatingIncomeLoss_1_Q2_USD":-6330791.0,"NotesPayableCurrent_0_Q2_USD":4727662.0,"NotesPayable_0_Q2_USD":null,"InterestExpenseRelatedParty_2_Q2_USD":927.0,"InterestPaidNet_2_Q2_USD":36462.0,"InvestmentIncomeInterest_1_Q2_USD":8487.0,"InvestmentIncomeInterest_2_Q2_USD":15597.0,"Liabilities_0_Q2_USD":17516675.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":183136138.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":24181.0,"LiabilitiesCurrent_0_Q2_USD":6202158.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-5156.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-9897151.0,"NetIncomeLoss_2_Q2_USD":-16994910.0,"NetIncomeLoss_1_Q2_USD":-6582941.0,"NonoperatingIncomeExpense_1_Q2_USD":-252150.0,"NonoperatingIncomeExpense_2_Q2_USD":-3159412.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":2950741.0,"OtherAssetsNoncurrent_0_Q2_USD":167848871.0,"OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_1_Q2_USD":3990.0,"OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_2_Q2_USD":7983.0,"PropertyPlantAndEquipmentOther_0_Q2_USD":668723.0,"RelatedPartyCosts_1_Q2_USD":718500.0,"RelatedPartyCosts_2_Q2_USD":3537000.0,"RepaymentsOfOtherDebt_2_Q2_USD":227598.0,"ResearchAndDevelopmentExpense_2_Q2_USD":5150328.0,"ResearchAndDevelopmentExpense_1_Q2_USD":2144085.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":668723.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-107906715.0,"ShareBasedCompensation_1_Q2_USD":2043292.0,"StockholdersEquity_0_Q2_USD":165619463.0,"StockIssuedDuringPeriodSharesIssuedForServices_1_Q2_shares":60000.0,"StockIssuedDuringPeriodSharesIssuedForServices_2_Q2_shares":60000.0,"StockIssuedDuringPeriodSharesNewIssues_1_Q2_shares":277340.0,"StockIssuedDuringPeriodSharesNewIssues_2_Q2_shares":277340.0,"ShareBasedCompensation_2_Q2_USD":4771267.0,"InterestExpenseOther_2_Q2_USD":36453.0,"PropertyPlantAndEquipmentGross_0_Q2_USD":985181.0,"ProceedsFromWarrantExercises_2_Q2_USD":130000.0,"OtherGeneralExpense_1_Q2_USD":6330791.0,"OtherGeneralExpense_2_Q2_USD":13835464.0,"OtherIndefiniteLivedIntangibleAssets_0_Q2_USD":166464000.0,"OtherLiabilitiesCurrent_0_Q2_USD":499875.0,"OtherReceivablesNetCurrent_0_Q2_USD":null,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":5156.0,"ProfitLoss_2_Q2_USD":-16994910.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"PreferredStockSharesIssued_0_Q2_shares":0.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"PreferredStockValue_0_Q2_USD":null,"PrepaidExpenseCurrent_0_Q2_USD":910637.0,"ProceedsFromIssuanceOfCommonStock_2_Q2_USD":74054.0,"ProceedsFromIssuanceOrSaleOfEquity_2_Q2_USD":3048339.0,"PreferredStockSharesAuthorized_0_Q2_shares":10000000.0,"InterestExpenseOther_1_Q2_USD":18181.0,"InterestExpenseDebt_2_Q2_USD":183121.0,"InterestExpenseDebt_1_Q2_USD":93382.0,"CommonStockCapitalSharesReservedForFutureIssuance_0_Q2_shares":17414.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"CommonStockSharesAuthorized_0_Q2_shares":100000000.0,"CommonStockSharesIssued_0_Q2_shares":52633267.0,"CommonStockSharesOutstanding_0_Q2_shares":52633267.0,"CommonStockValue_0_Q2_USD":5263.0,"CommitmentsAndContingencies_0_Q2_USD":null,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-6586931.0,"ConvertibleLongTermNotesPayable_0_Q2_USD":1200000.0,"ConvertibleNotesPayable_0_Q2_USD":1200000.0,"DepositsAssetsNoncurrent_0_Q2_USD":31494.0,"Depreciation_1_Q2_USD":27990.0,"Depreciation_2_Q2_USD":55796.0,"DepreciationAndAmortization_2_Q2_USD":63538.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-17002893.0,"DepreciationDepletionAndAmortization_1_Q2_USD":31805.0,"ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_2_Q2_USD":-2991897.0,"CashCashEquivalentsAndShortTermInvestments_0_Q2_USD":13423820.0,"AccruedLiabilitiesCurrent_0_Q2_USD":504383.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q2_USD":316457.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":-18817.0,"AdditionalPaidInCapital_0_Q2_USD":273539732.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":2043292.0,"AmortizationOfDebtDiscountPremium_1_Q2_USD":74274.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":-6956503.0,"AmortizationOfDebtDiscountPremium_2_Q2_USD":148548.0,"AmortizationOfIntangibleAssets_2_Q2_USD":7741.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":7125894.0,"Assets_0_Q2_USD":183136138.0,"AssetsCurrent_0_Q2_USD":14618544.0,"BusinessCombinationContingentConsiderationLiabilityNoncurrent_0_Q2_USD":9029842.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":13707907.0,"AmortizationOfIntangibleAssets_1_Q2_USD":3814.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":52321982.0,"DepreciationDepletionAndAmortization_2_Q2_USD":63538.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-0.33,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1_Q2_USD":-6582941.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2_Q2_USD":-16994876.0,"IncomeTaxesPaidNet_2_Q2_USD":34.0,"IncomeTaxExpenseBenefit_1_Q2_USD":null,"IncomeTaxExpenseBenefit_2_Q2_USD":34.0,"IncreaseDecreaseInAccountsAndOtherReceivables_2_Q2_USD":-1640.0,"Goodwill_0_Q2_USD":11640000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":-153810.0,"IncreaseDecreaseInOperatingLiabilities_2_Q2_USD":-143580.0,"IncreaseDecreaseInOtherCurrentLiabilities_2_Q2_USD":-30004.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":11812.0,"IndefiniteLivedIntangibleAssetsExcludingGoodwill_0_Q2_USD":154824000.0,"InterestExpense_1_Q2_USD":93382.0,"InterestExpense_2_Q2_USD":183121.0,"IncreaseDecreaseInAccruedLiabilities_2_Q2_USD":-677939.0,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.13,"GeneralAndAdministrativeExpense_2_Q2_USD":8621598.0,"ForeignCurrencyTransactionGainLossRealized_2_Q2_USD":9.0,"EffectOfExchangeRateOnCashAndCashEquivalents_2_Q2_USD":-4937.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0_Q2_USD":8571250.0,"FinanceLeaseRightOfUseAssetAmortization_2_Q2_USD":138014.0,"FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_0_Q2_USD":null,"FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0_Q2_USD":4661.0,"FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0_Q2_USD":5290.0,"GeneralAndAdministrativeExpense_1_Q2_USD":4154901.0,"FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0_Q2_USD":15154.0,"FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0_Q2_USD":15154.0,"FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_2_Q2_USD":-2752.0,"FiniteLivedIntangibleAssetsGross_0_Q2_USD":55413.0,"FiniteLivedIntangibleAssetsNet_0_Q2_USD":55413.0,"ForeignCurrencyTransactionGainLossBeforeTax_1_Q2_USD":3990.0,"ForeignCurrencyTransactionGainLossRealized_1_Q2_USD":null,"FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0_Q2_USD":15154.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":52270821.0,"Ticker":"ENOB","CIK":"1527728","name":"ENOCHIAN BIOSCIENCES INC","OfficialName":"Enochian Biosciences Inc. Common Stock","form":"10-Q","period":"20211231","fy":"2022.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"398960164.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20220214"}]